Multiple Myeloma

Expert faculty review and share their insights on key findings in multiple myeloma presented at the 2023 ASH Annual Meeting.

Share

Program Content

Activities

  • Multiple Myeloma
    Conference to Clinic: Multiple Myeloma
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 09, 2024

  • ASH 2023 Multiple Myeloma
    Conference to Clinic: Expert Analysis of the Top Multiple Myeloma Abstracts From the 2023 ASH Annual Meeting
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 07, 2024

    Expires: March 06, 2025

Activities

CENTAURUS Final Analysis
CENTAURUS: Final Analysis of Phase II Study With Daratumumab Monotherapy in Intermediate- or High-Risk Smoldering MM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

IsKia EMN24 in ND MM
IsKia EMN24: Phase III Trial of IsaKRd vs KRd in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

LINKER-MM1 Update
LINKER-MM1 Update: Phase I/II Trial of Anti-BCMAxCD3 Bispecific Antibody Linvoseltamab in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

DRVd vs RVd Real World
D-RVd vs RVd for Newly Diagnosed Transplant-Eligible Patients With Multiple Myeloma: Real-world Outcomes
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

PERSEUS Primary Analysis
PERSEUS: Primary Analysis of Phase III Trial With VRd ± Daratumumab in Patients With Newly Diagnosed Multiple Myeloma Eligible for ASCT
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

MonumenTAL-1 Modified Dosing
MonumenTAL-1: Impact of Dose Modification on Safety and Efficacy of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2023

VenDd in t(11;14) RR MM
Phase I/II Trial of Venetoclax/Dara/Dex (VenDd) vs Bortezomib/Dara/Dex (DVd) in t(11;14) R/R MM: Updated Analysis of MRD Negativity
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.